|
|
|
|
|||||
|
|
|
BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026.
| The Stifel 2026 Virtual CNS Forum | |
| Format: | Company presentation |
| Day/Time: | Wednesday, March 18 at 8.30 AM ET |
| Webcast: | Webcast Link: |
| https://event.summitcast.com/view/4Ggc9Rmi4GQpDPGZwDp8g8/DdYPDYEQLLU6kp2AWRS6bu | |
If you are interested in a virtual meeting with the Minerva team during the conference, please reach out to your Stifel representative.
A replay of the presentation will be available on the Company's Investors & Media Events and Presentations webpage for ninety days following the event.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
Contacts:
Investor inquiries:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
[email protected]
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
[email protected]
| 3 hours | |
| Mar-11 | |
| Mar-11 | |
| Mar-04 | |
| Feb-04 | |
| Jan-26 | |
| Nov-19 | |
| Nov-05 | |
| Nov-05 | |
| Oct-21 |
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
NERV +140.98%
GlobeNewswire
|
| Aug-14 | |
| Aug-14 | |
| May-13 | |
| May-13 | |
| Feb-25 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about Finviz Elite